文献速递肺外科

早期EGFR突变非小细胞肺癌:肺叶与亚肺叶切除比较

Lobar vs Sublobar Lung Resection for Early-Stage Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2026-04-01

该研究基于2021-2022年全国医院数据集,纳入≤2cm的NSCLC成人患者6918例,比较亚肺叶与肺叶切除的3年总生存。倾向评分匹配后,EGFR突变患者两种切除范围生存相似,而EGFR野生型患者亚肺叶切除生存更差。

要点

  • EGFR突变患者亚肺叶与肺叶切除3年总生存相似(95.3% vs 93.7%,P=.34)。
  • EGFR野生型患者亚肺叶切除生存劣于肺叶切除(84.5% vs 88.3%,P=.002)。
  • 术前EGFR检测可能有助于指导肺叶与亚肺叶切除的选择。

核心结论

  • EGFR突变早期NSCLC患者亚肺叶与肺叶切除生存相似,而野生型患者亚肺叶切除生存更差。
  • 术前EGFR检测可能辅助手术范围决策。

研究设计与样本

  • 回顾性队列研究,使用2021-2022年全国医院数据集。
  • 纳入≤2cm的NSCLC成人患者6918例,亚肺叶切除2673例(38.6%),肺叶切除4245例(61.4%)。
  • 采用倾向评分匹配平衡人口学和肿瘤特征,Kaplan-Meier法估计总生存。

主要发现

  • EGFR突变患者中,亚肺叶与肺叶切除3年总生存相似(95.3% vs 93.7%,P=.34)。
  • EGFR野生型患者中,亚肺叶切除3年总生存低于肺叶切除(84.5% vs 88.3%,P=.002)。
  • 无论切除范围,EGFR突变患者总生存优于野生型(94.3% vs 86.8%,P<.001)。
  • EGFR突变患者更常见于女性(74.3% vs 62.0%,P<.001)和亚洲人群(13.9% vs 3.2%,P<.001)。

临床怎么用

  • 对于≤2cm的早期NSCLC,术前EGFR检测可能帮助识别适合亚肺叶切除的EGFR突变患者。
  • EGFR野生型患者选择亚肺叶切除需谨慎,因生存可能劣于肺叶切除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized controlled trials have shown that sublobar resections for small peripheral non-small cell lung cancer (NSCLC) are oncologically noninferior to lobar resections. However, these studies did not factor in epidermal growth factor receptor (EGFR) mutations. In this context, we sought to determine survival differences between sublobar and lobar resection for EGFR-mutant vs wild-type NSCLC. METHODS: We identified adult patients with ≤2 cm NSCLC tested for EGFR mutations between 2021 and 2022 from a national hospital-based data set. Patients were split into sublobar and lobar resection groups. The main outcome was 3-year overall survival. We used propensity score matching to account for patient demographic and tumor characteristics. Kaplan-Meier survival analyses were used to estimate overall survival. RESULTS: There were 6918 patients, with 2673 (38.6%) undergoing sublobar resections and 4245 (61.4%) undergoing lobar resections. EGFR mutations were present in 380 (14.2%) sublobar resections and in 715 (16.8%) lobar resections. Patients with EGFR-mutant NSCLC were more likely to be women (74.3% vs 62.0%, P < .001) and Asian (13.9% vs 3.2%, P < .001). Regardless of resection extent, patients with EGFR-mutant lung cancer had better overall survival compared with EGFR-wild-type tumors (94.3% vs 86.8%, P < .001). Sublobar and lobar resections for EGFR-mutant tumors had similar survival (95.3% vs 93.7%, P = .34), whereas sublobar resections for EGFR-wild-type tumors had worse survival than lobar resections (84.5% vs 88.3%, P = .002). CONCLUSIONS: EGFR testing before surgery may help guide surgical decision-making when selecting lobar vs sublobar resections.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Pohlman A, Odeh B, Raad W, et al. Lobar vs Sublobar Lung Resection for Early-Stage Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer. Ann Thorac Surg. 2026. PMID: 41933780. doi:10.1016/j.athoracsur.2026.03.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。